In another study, a significant decrease in the mean BMI was found in 20 prepubertal children (4–12 years) with epilepsy without any significant change in serum glucose, ghrelin, neuropeptide Y, or insulin levels at the third and six months of the administration of topiramate compared to pre-treatment levels. This evidence concerns the gene GHRL and epilepsy.